FDA Launches Green List To Simplify Import of Compliant GLP-1 API for Pharmacy Compounding - JD Supra
FDA has launched a 'Green List' to simplify importation of compliant GLP-1 APIs for pharmacy compounding, potentially easing supply chain constraints for compounders.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Pharmacy compounders (including 503B outsourcing facilities) and API importers dealing with GLP-1 products. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA introduced a 'Green List' mechanism to streamline import of compliant GLP-1 APIs for compounding, reducing regulatory friction.
Who it affects
Pharmacy compounders (including 503B outsourcing facilities) and API importers dealing with GLP-1 products.
What you must do
Review the Green List criteria and assess whether your current GLP-1 API suppliers are listed; if not, consider sourcing from listed suppliers to simplify imports.
Deadline
Not specified in the provided text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Final Debarment Order: Rahim Shafa; Denial of Hearing
- 5th Circ. Backs FDA, Pharma Cos. In GLP-1 Shortage Fight - Law360
- FDA proposes streamlined requirements for ‘hub-and-spoke’ manufacturing models - BioSpace
- FDA Proposes Foreign Manufacturing Establishment Registration and Product Listing Requirements - regulatoryoversight.com
- Experimental Drugs Without FDA Approval Are Now Legal in Montana - vice.com